Empagliflozin reduces renal lipotoxicity in experimental Alport syndrome
M. Ge, J. Molina, J. J. Kim, S. K. Mallela, A. Ahmad, J. Varona Santos, H. Al-Ali, A. Mitrofanova, K. Sharma, F. Fontanesi, S. Merscher, A. Fornoni
This study shows empagliflozin reduces renal lipotoxicity and improves kidney function in experimental Alport syndrome by shifting energy substrates from glucose to fatty acids in podocytes.
bioRxiv · Oct 4, 2022Cell Biology